Biocept to Collaborate with Quest Diagnostics to Provide Advanced NGS-Based Liquid Biopsy Testing for Patients with Lung Cancer
June 22 2021 - 8:17AM
Business Wire
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, today announced a
collaboration with Quest Diagnostics (NYSE: DGX) to provide
laboratory testing services to Quest patients for its Target
Selector™ NGS-based liquid biopsy targeted lung cancer panel. Quest
Diagnostics is the leading provider of diagnostic information
services, including in advanced diagnostics.
The Biocept Target Selector NGS-based liquid biopsy assay is a
less invasive, lab developed test that can be used for genomic
profiling in patients with advanced non-small cell lung cancer
(NSCLC) to help qualify them for advanced targeted therapies and
monitor the effectiveness of treatment. With a physician order,
patients will be able to provide a blood specimen for testing at
one of Quest’s 2,200 conveniently located patient service centers
across the United States. The two parties expect the service to be
available to Quest Diagnostics’ providers and patients in the
fourth quarter of 2021.
"We are pleased to expand Biocept’s relationship with Quest
Diagnostics, as we believe its expertise and reach will allow us to
serve more patients and potentially grow our customer base,” said
Michael Nall, President and CEO of Biocept. “Quest shares our focus
on improving care for patients with lung cancer, and this agreement
provides a strong collaborator to help us provide oncologists with
the answers they need to create more personalized, responsive
treatment plans for their patients.”
“Lung cancer is one of the most prevalent and deadliest
cancers,” said Kristie Dolan, General Manager, Oncology Franchise,
Quest Diagnostics. “Better tools to aid in therapy selection and
monitoring are urgently needed to improve patient outcomes, which
is why we are so excited to work with Biocept on this focused test.
Quest has the national scale, oncology expertise and network
provider relationships to broaden access to this important
innovation in order to potentially improve care for patients in
treatment for lung cancer."
Biocept Target Selector NGS-based targeted lung cancer panel
includes the most prevalent clinically actionable genes for NSCLC.
It combines Biocept’s liquid biopsy biomarker testing expertise
with next-generation sequencing and decision support resources. The
NGS solution is targeted and actionable—approximately 70% of the
biomarkers investigated are based on National Comprehensive Cancer
Center guidelines and/or FDA-approved therapies.
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers. In addition to its broad portfolio of
blood-based liquid biopsy assays, Biocept has developed the CNSide™
cerebrospinal fluid assay that detects cancer that has metastasized
to the central nervous system. Biocept’s patented Target Selector™
technology captures and quantitatively analyzes CSF tumor cells for
tumor-associated molecular markers, using technology first
developed for use in blood. Biocept also is leveraging its
molecular diagnostic capabilities to offer nationwide COVID-19
RT-PCR testing to support public health efforts during this
unprecedented pandemic. For more information, visit
www.biocept.com. Follow Biocept on Facebook, LinkedIn and
Twitter.
Forward-Looking Statements Disclaimer
This news release contains forward-looking statements that are
based upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
be correct. Forward-looking statements are generally identifiable
by the use of words like "will," ""expect," "believe," or
"potentially," or the negative of these words or other variations
on these words or comparable terminology. To the extent that
statements in this news release are not strictly historical,
including, without limitation, statements regarding the expectation
that the Biocept Target Selector NGS-based liquid biopsy assay will
be available to Quest Diagnostics providers and patients in the
fourth quarter of 2021, Biocept’s belief that its collaboration
with Quest Diagnostics will allow Biocept to serve more patients
and potentially grow its customer base, the ability of the Biocept
Target Selector NGS-based liquid biopsy assay to potentially
improve care for patients in treatment for lung cancer, and our
ability to provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers, such statements are forward-looking, and are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The reader is cautioned
not to put undue reliance on these forward-looking statements, as
these statements are subject to numerous risks and uncertainties,
including the risk that the collaboration with Quest Diagnostics
will not result in broadened patient access to the Biocept Target
Selector NGS-based liquid biopsy assay and the risk that our
products and services may not perform as expected. These and other
risks are described in greater detail under the "Risk Factors"
heading of our Quarterly Report on Form 10-Q for the quarter ended
March 31, 2021, as field with the Securities and Exchange
Commission (SEC) on May 12, 2021. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this news release. We
do not plan to update any such forward-looking statements and
expressly disclaim any duty to update the information contained in
this press release except as required by law. Readers are advised
to review our filings with the SEC at http://www.sec.gov/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210622005296/en/
Media Contact: Andrea Sampson, Sampson PR Group
asampson@sampsonprgroup.com, 562-304-0301
Investor Contact: Jody Cain, LHA Investor Relations
Jcain@lhai.com, 310-691-7100
For Quest Diagnostics: Jennifer Petrella
mediacontact@questdiagnostics.com, 973-520-2800
Quest Diagnostics (NYSE:DGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quest Diagnostics (NYSE:DGX)
Historical Stock Chart
From Apr 2023 to Apr 2024